
An international study has found an increased risk of Guillain-Barré syndrome (GBS) following SARS-CoV-2 infection and after vaccination with adenoviral …

Hansa Biopharma will present data from its 15-HMedIdeS-09 phase 2 study of imlifidase for treating Guillain-Barré syndrome (GBS) at the …
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions

